Cargando…
Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report
Embryonal rhabdomyosarcoma (ERMS) is associated with a low prevalence, poor prognosis, and limited treatment efficacy. Here, we report a case of a 21-year-old male whose disease relapsed in the thoracic cavity following traditional chemotherapy. The patient received eight sequential cycles of tradit...
Autores principales: | Xing, Tuo, Zhang, Yalei, Li, Xukai, Guo, Minzhang, Liang, Wenhua, He, Jianxing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867777/ https://www.ncbi.nlm.nih.gov/pubmed/33569329 http://dx.doi.org/10.21037/tlcr-19-644 |
Ejemplares similares
-
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020) -
Olaratumab’s failure in soft tissue sarcoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2021) -
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020) -
Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019) -
Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)